Thursday, August 13, 2015 11:09:09 AM
Bernardino observed, “We believe Rexahn will continue to make important advances in its clinical development and pipeline programs in 2H15. We anticipate the achievement of multiple clinical development milestones in 2H15, and with the shares down 20% YTD, we believe RNN shares are an attractive value proposition (enterprise value of $76MM for RNN vs. a mean $328MM for comparable oncology-focused companies).”
“RNN reported a net loss of $3.2MM, or ($0.02)/sh, which was in line with our estimates. As of June 30, 2015, RNN had cash and equivalents of $26.0MM. In our view, Rexahn practices austerity that we believe make its cash sufficient to fund operations through 2H16.”, the analyst added. Less
Sentiment: Hold
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM